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We	 report	 Buruli	 ulcer	 in	 a	 man	 in	 the	 Netherlands.	 
Phenotyping	 of	 samples	 indicate	 the	 Buruli	 pathogen	 
was	 acquired	 in	 Suriname	 and	 activated	 by	 trauma	 on	
return	 to	 the	Netherlands.	Awareness	 of	 this	 disease	 by	
clinicians	 in	 non–Buruli	 ulcer–endemic	 areas	 is	 critical	 
for	identification.
Buruli ulcer (BU) is a potentially disabling affliction of inhabitants of tropical wetlands (1) caused by Myco-
bacterium ulcerans and characterized by necrosis of skin, 
subcutaneous tissue, and sometimes bone. Major foci are in 
West and Central Africa and minor endemic foci in Austra-
lia, Southeast Asia, Mexico, and South America.
BU is rare in South America; 15 cases were reported 
in Peru since 1996 (1; H. Guerra, pers. comm.), and 242 
cases were reported during 1969–2011 in French Guiana 
(2), which is bordered by Suriname to the west. Myco-
bacterial ulcers have been seen in Suriname in the past 
(R.F.M. Lai, A. Fat, L. Sabajo, pers. comm.), but these 
cases were not confirmed by laboratory tests. We report 
a case of BU in a patient from Suriname diagnosed in 
the Netherlands.
The Case-Patient
In February 2013, a 70-year-old man sought care at the 
University of Amsterdam Department of Dermatology for 
a neuropathic ulcer on his left foot. It was determined that 
he had a neuropathic ulcer, a complication of nerve damage 
caused by leprosy, for which he was treated successfully. 
Data from his medical history were recovered and reexam-
ined at this time.
He was a native of Suriname, where he lived until he 
moved to the Netherlands 1977. He had multiple instances 
of treatment for skin infections, beginning with a diagnosis 
of leprosy (Hansen disease, caused by the mycobacterium 
M. leprae) when he was 10 years of age. 
He was treated continuously with dapsone during 
1952–1978. In 1977, he moved to Groningen, the Neth-
erlands, and clofazimine was added to his treatment for 
leprosy for 6 months. In February 1982, he moved to Am-
sterdam and sought routine follow-up care for leprosy at 
the University of Amsterdam Department of Dermatol-
ogy, and quiescent borderline lepromatous leprosy was 
diagnosed. He was treated during February 1982–February 
1983 with a triple therapy consisting of rifampin, dapsone, 
and clofazimine.
In 1984, the man traveled to Paramaribo and Coro-
nie in Suriname, where he stayed for 4 weeks during the 
spring season. During that time, he fished in creeks.  In 
December 1984, he sought treatment again at the Uni-
versity of Amsterdam Department of Dermatology for a 
painful red swelling on the dorsal side of the right wrist 
after he had scratched it on a rough wall 5 weeks earlier, 
in mid-November. Beginning in February 1985, the pa-
tient had signs of infection of the wound, including con-
spicuous edematous swelling of the hand. Radiographic 
imaging showed no signs of osteomyelitis. The patient 
was treated with flucloxacillin; the symptoms subsided. 
However, during April 26–May 11, 1985, the patient ex-
perienced recurrent infection with abscess formation. A 
biopsy was taken, and an acid-fast bacilli (AFB) smear 
and culture for nontuberculous mycobacteria were done. 
The histopathology report indicated scarring dermis and 
mixed cell infiltrate, leucocytoclastic vasculitis, fibrinoid 
changes, and some diffusely spread histiocytes. AFB 
staining was negative. On June 3, partly dry wounds, 1 
deep ulcer, fistula formation, and spontaneous drain-
age of another lesion were documented. The wound was 
cultured, and amoxicillin and clavulinic acid 4 times 
daily for 3 weeks was prescribed; after that time, the 
patient’s treatment for related conditions consisted of lo-
cal wound care. After 6 weeks’ incubation, the mycobac-
terial culture was positive at 30°C but negative at 37°C 
and 45°C. In August, ulcers were still present, and mul-
tiple nodules at the underarm and an enlarged lymph node 
at the elbow were palpable. Infection with M. ulcerans 
was suspected clinically.
On January 20, 1986, the isolate was sent to the Insti-
tute of Tropical Medicine of Antwerp and was identified 
as M. ulcerans ITM 842 according to phenotypic charac-
teristics (3). The isolate was further analyzed by several 
genotypic methods (3–6). By April 7, 1986, the ulcers were 
nearly completely closed. 
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We describe a patient infected with M. ulcerans strain ITM 
842. Phenotypic characteristics of isolates from Suriname 
and French Guiana are identical, whereas isolates originat-
ing in Africa, Australia, and Asia have different phenotypic 
characteristics (3). Variable-number tandem-repeat geno-
typic analysis had been shown to discriminate the Suriname 
isolate from French Guiana isolates and from mycolactone-
producing M. marinum (4,5). Results confirmed that this 
isolate was different from M. ulcerans isolates from other 
geographic origins, albeit closely related to M. ulcerans 
strains from French Guiana by genetic characteristics (4,5). 
These results suggest that the patient acquired his infection 
in Suriname.
The incubation period of primary BU is estimated to 
be 2–3 months, but latency of the disease can span years. 
Persons who were in an area to which BU is endemic 
months to years earlier can manifest BU in a traumatized 
body site (6,7).
Co-infections with leprosy and BU have been de-
scribed, but rarely (8). During 1952–1977, the patient was 
treated with dapsone monotherapy. Additionally, he re-
ceived clofazimine for 6 months upon his arrival in the Neth-
erlands. Subsequently, during February 1982–February 
1983, he was treated with a triple therapy consisting of 
rifampin, dapsone, and clofazimine. Treatment of BU pa-
tients with dapsone has not been properly evaluated in hu-
mans (9), and clofazimine is not indicated in the treatment 
of patients with BU (10); however, rifampin is highly bac-
tericidal against this organism (11).
If the patient was infected with M. ulcerans before his 
arrival in the Netherlands in 1977, it is unlikely that the 
dapsone and clofazimine that he received for treatment 
of leprosy could have controlled the infection. Whether 
or not he had been infected with M. ulcerans when he 
first arrived in the Netherlands, treatment for 1 year with 
rifampin and dapsone before he returned to Suriname for 
4 weeks in 1984 would have been expected to have killed 
any M. ulcerans. Thus, the most likely hypothesis is that 
he acquired BU infection during the 4 weeks he spent in 
Suriname in 1984, and that the scratch obtained against 
a rough wall in November 1984 in the Netherlands re-
activated a latent infection. It is unlikely that the rough 
wall was contaminated by M. ulcerans, because BU is not 
considered prevalent in Europe. 
There are many similarities between this case and that 
reported by Lindo and Daniels (7). Both patients mani-
fested symptoms of BU after having left a disease-endemic 
area, and in both patients, the lesion developed at the site of 
a trauma that occurred in a non–disease-endemic country.
Correct laboratory confirmation remains essential to 
confirm the discovery of new foci of BU, and the use of 
genetic mapping can provide additional information about 
the geographical location in which patients were infected. 
The importance of laboratory confirmation of BU has been 
emphasized by the World Health Organization’s manual 
for the laboratory diagnosis of BU (12).The study of im-
ported cases, and in particular this case from Suriname, has 
enabled us to acquire more knowledge regarding latency 
and reactivation of the disease, and the existence of new 
foci. As in the report by Meyers et al (13), this case report 
emphasizes the role of trauma to the skin in the delayed 
manifestation of this disease caused by M. ulcerans.
Reports from European countries, Canada, America, 
and Australia describe travelers visiting friends or rela-
tives in BU-endemic countries who manifested BU upon 
return to a non–disease-endemic area (14,15). Thus, BU 
may be diagnosed in patients late, or not diagnosed, in 
non–disease-endemic countries, where health care profes-
sionals are usually not familiar with the condition or its 
causal organism. Delayed diagnosis often leads to severe 
disabilities. In countries where BU is uncommon, the cli-
nician’s consideration of the patient’s recent travel his-
tory and awareness of cutaneous and bone lesions of BU 
are needed for accurate testing, diagnosis, and treatment 
of the patient.
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